Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients

BACKGROUND: The benefit of adjuvant aromatase inhibitors (AI) vs tamoxifen has been investigated in randomized clinical trials for premenopausal and postmenopausal patients with early, estrogen receptor–positive (ER+) breast cancer. The optimal endocrine treatment for chemotherapy-treated perimenopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dackus, Gwen M H E, Jóźwiak, Katarzyna, Sonke, Gabe S, van der Wall, Elsken, van Diest, Paul J, Siesling, Sabine, Hauptmann, Michael, Linn, Sabine C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562974/
https://www.ncbi.nlm.nih.gov/pubmed/34101806
http://dx.doi.org/10.1093/jnci/djab091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562974/
https://www.ncbi.nlm.nih.gov/pubmed/34101806
http://dx.doi.org/10.1093/jnci/djab091

Ejemplares similares